<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="8772">raloxifene</z:chebi> on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following experimental <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) was investigated in a rat model </plain></SENT>
<SENT sid="1" pm="."><plain>Seven groups of seven rats underwent no SAH, no treatment; SAH only; SAH plus vehicle; SAH plus 3 days intraperitoneal <z:chebi fb="0" ids="8772">raloxifene</z:chebi> treatment; SAH plus 4 days intraperitoneal <z:chebi fb="0" ids="8772">raloxifene</z:chebi> treatment; SAH plus 3 days intrathecal <z:chebi fb="0" ids="8772">raloxifene</z:chebi> treatment; and SAH plus 4 days intrathecal <z:chebi fb="0" ids="8772">raloxifene</z:chebi> treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The basilar artery cross-sectional areas were measured at 72 or 96 hours following SAH </plain></SENT>
<SENT sid="3" pm="."><plain>The results showed <z:chebi fb="0" ids="8772">raloxifene</z:chebi> decreased SAH-induced <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in <z:hpo ids='HP_0000001'>all</z:hpo> treatment groups, and suggested no difference between intraperitoneal and intrathecal application, or between 3 days and 4 days of <z:chebi fb="0" ids="8772">raloxifene</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The present study demonstrates that <z:chebi fb="0" ids="8772">raloxifene</z:chebi> is a potential therapeutic agent against <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after SAH </plain></SENT>
</text></document>